, Volume 30, Issue 3, pp 462–464 | Cite as

Protective immunity against hepatitis B virus infection in a group of vaccinated Sri Lankan military service men following a complete course of vaccination

  • Faseeha NoordeenEmail author
  • H. M. Sagara Karunaratne
  • Varuna Nawaratne
  • F. N. Nagoor Pitchai
  • S. W. P. Lakmini Daulagala
  • A. M. S. Bandara Abeykoon
Short Communication


Vaccination is the appropriate measure to protect military personnel against the hepatitis B virus (HBV) infection. Testing the military personnel for anti-HBs levels after vaccination is vital in re-vaccinating those that have not developed protective immunity. The aim of the current study was to determine the immunity in a group of vaccinated Sri Lankan military personnel (n = 150; age = 26–44 years) following a complete course of hepatitis B virus surface antigen (HBsAg) vaccination by assessing the antibodies against HBsAg (anti-HBs) levels. Three months after the last dose of the vaccination, blood samples were collected from the study population and tested for anti-HBs levels using a commercially available ELISA. Of the 150 military service men tested, 139 (92.67%) had anti-HBs levels higher than 10 mIU/mL, WHO approved levels for protective immunity against HBV infection. Of the 139 that had sufficient anti-HBs levels, 24% (36/150) had anti-HBs levels between 10 and 100 mIU/mL and 68.67% (103/150) had anti-HBs levels > 100 mIU/mL. Overall, 7.33% (11/150) participants had anti-HBs levels < 10 mIU/mL. Sero-conversion to > 10 mIU/mL anti-HBs was more than 90% in those that were less than 40 years of age and it was less than 90% in those that were more than 40 years of age.


Hepatitis B virus HBsAg immunization Protective immunity Sri Lanka 



This study was supported by Postgraduate Institute of Science, University of Peradeniya, Sri Lanka.


  1. 1.
    Abedi F, Madani H, Asadi A, Nejatizadeh A. Significance of blood related high risk behaviors and horizontal transmission of hepatitis B virus in Iran. Arch Virol. 2011;15:629–35.CrossRefGoogle Scholar
  2. 2.
    Ahad A, Alim A, Guho A, Islam QT, Azad KBK. Role of booster dose on antibody titer after recombinant hepatitis B vaccine. J Med. 2009;10:67–76.CrossRefGoogle Scholar
  3. 3.
    Baddevithana AK, Noordeen F, Mendis CM, Abeykoon AMSB. Immune response to hepatitis B vaccine in a group of vaccinees in the Faculty of Allied Health Sciences of the University of Peradeniya. Sri Lankan J Infect Dis. 2015;5:7–12.CrossRefGoogle Scholar
  4. 4.
    Chathuranga LS, Noordeen F, Abeykoon AMSB. Immune response to hepatitis B vaccine in a group of health care workers in Sri Lanka. Int J Infect Dis. 2013. Scholar
  5. 5.
    Esteghamati A, Keshtkar AA, Nadjafi L, Gouya MM, Salaramoli M, Roshandel G, et al. Hepatitis B vaccination coverage among Iranian children aged 15–26 months in 2006. East Mediterr Health J. 2011;17:93–100.CrossRefGoogle Scholar
  6. 6.
    Fathimoghaddam F, Hedayati MMR, Bidkhori HR, Bidkhori HR, Ahmadi S, Sima HR. Prevalence of hepatitis B antigen positivity in the general population of Mashhad, Iran. Hepat Mon. 2011;11:346–50.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329–39.CrossRefGoogle Scholar
  8. 8.
    Keeffe EB. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am J Med. 2005;118:215–75.CrossRefGoogle Scholar
  9. 9.
    Kunal Das RK, Gupta Kumar V, Kar P. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over 40 years of age and response to a booster among non-responders. World J Gastroenterol. 2003;9:1132–4.CrossRefGoogle Scholar
  10. 10.
    Livramento AD, Cordova CM, Scaraveli NG, Tonial GC, Spada C, Treitinger A. Anti-HBs levels among children and adolescents with complete immunization schedule against hepatitis B virus. A cross sectional study in Blumenau, State of Santa Catarina, Brazil, 2007–2008. Rev Soc Bras Med Trop. 2011;44:412–5.CrossRefGoogle Scholar
  11. 11.
    McMahon BJ, Bruden DL, Petersen KM, Hedberg CW, Hanson M, Osterholm MT. Antibody level and protection after hepatitis B vaccination. Result of a 15 years follow up. Ann Intern Med. 2005;142:333–41.CrossRefGoogle Scholar
  12. 12.
    Noordeen F. Hepatitis B virus infection: an insight into infection outcomes and recent treatment options. Virus Dis. 2015;26:1–8.CrossRefGoogle Scholar
  13. 13.
    Noordeen F, Pitchai FNN, Rafeek RA. A review of hepatitis B virus infection in Sri Lanka. Sri Lankan J Infect Dis. 2015;5:42–50.CrossRefGoogle Scholar
  14. 14.
    Perera J, Perera B, Gamage S. Seroconversion after hepatitis B vaccination in healthy young adults and the effect of a booster dose. Ceylon Med J. 2002;47:6–8.CrossRefGoogle Scholar
  15. 15.
    Piratheepkumar V, Kulendran S, Nadarajah S, Murugananthan K. Hepatitis B vaccine immunogenicity among nurses of a hospital. Ceylon Med J. 2014;59:59–60.CrossRefGoogle Scholar
  16. 16.
    Rendi WP, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, et al. Antibody response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel clinic based experience. Vaccine. 2001;19:2055–60.CrossRefGoogle Scholar
  17. 17.
    Wood RC, MacDonald KL, White KE, et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA. 1993;270:2935–72.CrossRefGoogle Scholar
  18. 18.
    Yu AS, Cheung RC, Keeff EB. Hepatitis B vaccines. Infect Dis Clin N Am. 2006;20:27–45.CrossRefGoogle Scholar

Copyright information

© Indian Virological Society 2019

Authors and Affiliations

  1. 1.Department of Microbiology, Faculty of MedicineUniversity of PeradeniyaPeradeniyaSri Lanka
  2. 2.Faculty of MedicineSir John Kotelawela Defence UniversityRatmalanaSri Lanka

Personalised recommendations